Literature DB >> 18694556

VEGFR3: a new target for antiangiogenesis therapy?

Timothy P Padera1, Rakesh K Jain.   

Abstract

VEGFR-3 signaling plays an important role in developmental, physiological, and pathological angiogenesis and lymphangiogenesis. Tammela et al. in Nature show that VEGFR-3, via Notch regulation, is present on endothelial tip cells and is critical to sprouting angiogenesis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18694556      PMCID： PMC4790102          DOI： 10.1016/j.devcel.2008.07.014

Source DB:  PubMed          Journal:  Dev Cell        ISSN： 1534-5807            Impact factor:   12.270


  9 in total

1.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries.

Authors:  Arndt F Siekmann; Nathan D Lawson
Journal:  Nature       Date:  2007-01-28       Impact factor: 49.962

3.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.

Authors:  Mats Hellström; Li-Kun Phng; Jennifer J Hofmann; Elisabet Wallgard; Leigh Coultas; Per Lindblom; Jackelyn Alva; Ann-Katrin Nilsson; Linda Karlsson; Nicholas Gaiano; Keejung Yoon; Janet Rossant; M Luisa Iruela-Arispe; Mattias Kalén; Holger Gerhardt; Christer Betsholtz
Journal:  Nature       Date:  2007-01-28       Impact factor: 49.962

4.  Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells.

Authors:  Jen-Liang Su; Pai-Sheng Chen; Ming-Hsien Chien; Poshen B Chen; Ya-Huey Chen; Chien-Chen Lai; Mien-Chie Hung; Min-Liang Kuo
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

Review 5.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

6.  Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.

Authors:  Pirjo Laakkonen; Marika Waltari; Tanja Holopainen; Takashi Takahashi; Bronislaw Pytowski; Philipp Steiner; Daniel Hicklin; Kris Persaud; James R Tonra; Larry Witte; Kari Alitalo
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

7.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.

Authors:  D J Dumont; L Jussila; J Taipale; A Lymboussaki; T Mustonen; K Pajusola; M Breitman; K Alitalo
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

8.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

9.  Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.

Authors:  Timothy P Padera; Angera H Kuo; Tohru Hoshida; Shan Liao; Jennifer Lobo; Kevin R Kozak; Dai Fukumura; Rakesh K Jain
Journal:  Mol Cancer Ther       Date:  2008-08-06       Impact factor: 6.261
  9 in total
  7 in total

1.  Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.

Authors:  Suphansa Sawamiphak; Sascha Seidel; Clara L Essmann; George A Wilkinson; Mara E Pitulescu; Till Acker; Amparo Acker-Palmer
Journal:  Nature       Date:  2010-05-05       Impact factor: 49.962

2.  Endothelial cells in the innate response to allergens and initiation of atopic asthma.

Authors:  Kewal Asosingh; Kelly Weiss; Kimberly Queisser; Nicholas Wanner; Mei Yin; Mark Aronica; Serpil Erzurum
Journal:  J Clin Invest       Date:  2018-06-18       Impact factor: 14.808

3.  Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.

Authors:  Roni Mamluk; Irvith M Carvajal; Brent A Morse; Henry Wong; Janette Abramowitz; Sharon Aslanian; Ai-Ching Lim; Jochem Gokemeijer; Michael J Storek; Joonsoo Lee; Michael Gosselin; Martin C Wright; Ray T Camphausen; Jack Wang; Yan Chen; Kathy Miller; Kerry Sanders; Sarah Short; Jeff Sperinde; Gargi Prasad; Stephen Williams; Robert Kerbel; John Ebos; Anthony Mutsaers; John D Mendlein; Alan S Harris; Eric S Furfine
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 4.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

5.  Fenofibrate inhibits the expression of VEGFC and VEGFR-3 in retinal pigmental epithelial cells exposed to hypoxia.

Authors:  Jianfeng Zhao; Y U Geng; Hairong Hua; Biyun Cun; Qianbo Chen; Xiaoting Xi; Liushu Yang; Yan Li
Journal:  Exp Ther Med       Date:  2015-08-21       Impact factor: 2.447

Review 6.  Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.

Authors:  Cheng Zhang; Ning Wang; Hor-Yue Tan; Wei Guo; Sha Li; Yibin Feng
Journal:  Integr Cancer Ther       Date:  2018-05-28       Impact factor: 3.279

7.  Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.

Authors:  Yunling Xu; Li Yuan; Judy Mak; Luc Pardanaud; Maresa Caunt; Ian Kasman; Bruno Larrivée; Raquel Del Toro; Steven Suchting; Alexander Medvinsky; Jillian Silva; Jian Yang; Jean-Léon Thomas; Alexander W Koch; Kari Alitalo; Anne Eichmann; Anil Bagri
Journal:  J Cell Biol       Date:  2010-01-11       Impact factor: 10.539
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.